Sequential administration of chemotherapy followed by radioimmunotherapy with Iodine-131-Tositumomab in untreated non-Hodgkin's lymphoma (NHL)

被引：0
|
作者：
Kostakoglu, L
Goldsmith, SJ
Vallabhajosula, S
Coleman, M
Morris, A
Link, BK
Kaminski, MS
Nadeau, K
Valente, N
Leonard, JP
机构：
[1] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA
[2] Corixa Corp, Redwood City, CA USA
[3] Univ Iowa, Ctr Canc, Iowa City, IA 52242 USA
[4] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 2001年 / 28卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OS78
引用
收藏
页码：981 / 981
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen (BTR)), in treatment of non-Hodgkin lymphoma (NHL)
    Flowers, C. R.
    Sambrook, J. C.
    Briggs, A.
    Osenenko, K.
    Wang, H.
    Dalal, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Preliminary results of a multicenter dosimetry, efficacy and safety study with iodine-131 tositumomab in treatment of non-Hodgkin's lymphoma (NHL)
    Kostakoglu, L
    Goldsmith, SJ
    Buchegger, F
    Lewington, V
    Leonard, JP
    Illidge, T
    Ketterer, N
    Kovacsovics, T
    Valente, N
    Bischof-Delaloye, A
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 979 - 979
  • [23] Iodine I 131 tositumomab for patients with follicular non-Hodgkin's lymphoma (NHL): Overall clinical trial experience by histology.
    Vose, JM
    Zelenetz, AD
    Rohatiner, A
    Knox, S
    Stagg, R
    Kroll, S
    Tidmarsh, G
    Kaminski, MS
    BLOOD, 1999, 94 (10) : 89A - 89A
  • [24] Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
    Davies, AJ
    Rohatiner, AZS
    Howell, S
    Britton, KE
    Owens, SE
    Micallef, IN
    Deakin, DP
    Carrington, BM
    Lawrance, JA
    Vinnicombe, S
    Mather, SJ
    Clayton, J
    Foley, R
    Jan, H
    Kroll, S
    Harris, M
    Amess, J
    Norton, AJ
    Lister, TA
    Radford, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1469 - 1479
  • [25] Tositumomab and 131I therapy in non-Hodgkin's lymphoma
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 : 128S - 140S
  • [26] Clinical experience of Weill Cornell Medical Center with 131I-tositumomab (Bexxar™) radioimmunotherapy in relapsed/refractory non-Hodgkin's lymphoma (NHL).
    Kostakoglu, L
    Leonard, JP
    Coleman, M
    Vallabhajosula, S
    Kroll, S
    Fiore, JM
    Scarano, D
    Hack, S
    Goldsmith, SJ
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 312P - 312P
  • [27] Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL)
    Weiden, PL
    Breitz, HB
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 40 (01) : 37 - 51
  • [28] CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma
    Leonard, John P.
    Gregory, Stephanie A.
    Smith, Hedy
    Horner, Thierry J.
    Williams, Vanessa C.
    Giampietro, Patricia
    Lin, Thomas S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (04): : 191 - 196
  • [29] Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma
    Dosik, AD
    Coleman, M
    Kostakoglu, L
    Furman, RR
    Fiore, JM
    Muss, D
    Niesvizky, R
    Shore, T
    Schuster, MW
    Stewart, P
    Vallabhajosula, S
    Goldsmith, SJ
    Leonard, JP
    CANCER, 2006, 106 (03) : 616 - 622
  • [30] Treatment procedure for iodine-131Labeled antibody for Non-Hodgkin's lymphoma (NHL)
    Nair, M
    Anderson, P
    Neumann, T
    Mark, R
    MEDICAL PHYSICS, 2004, 31 (06) : 1925 - 1925
12345